
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
“We wanted to compare outcomes between nursing home residents and community-dwelling older adults undergoing surgery for bladder and bowel dysfunction,” explains Anne M. Suskind, MD.
Anne M. Suskind, MD, discusses the


